CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial

August 1st, 2014 –14 patients enrolled in July brings total enrollment to over one-quarter of the 880 patients planned for enrollment by the end of 2015 CEL-SCI Corporation¬†(NYSE MKT: CVM)¬†today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and …